In a statement released late Tuesday, ZymoGenetics said the deal valued ZymoGenetics at $9.75 per share and that shareholders representing 37 percent of ZymoGenetics had agreed to put their shares into a tender offer that is scheduled to begin Thursday.
"We believe we will enhance the long-term potential of ZymoGenetics' portfolio of assets,"ZymoGenetics Chief Executive Officer Douglas Williams said,
Among the drugs ZymoGenetics has under development is one for hepatitis C called pegylated-interferon lambda. The drug, "if approved, could be an important contributor to Bristol-Myers Squibb's future growth," the statement said.
Bristol-Myer Squibb also obtains ZymoGenetics drug recothrom, which is used to control bleeding during surgical procedures.
Copyright 2010 United Press International, Inc. (UPI).